MADISON, Wis. -- (Business Wire)
The Centers for Medicare and Medicaid Services (CMS) has informed
representatives of Exact Sciences that next week the agency will be
issuing a correction to the 2015 lab fee schedule. Consistent with the
November 25th final payment decision, CMS will reimburse Cologuard based
on the national limit for CPT codes 82274, 81275 and 81315 which
combined lead to a total reimbursement amount of $500.76.
About Exact Sciences Corp.
Exact Sciences Corp. (NASDAQ: EXAS) is a molecular diagnostics company
focused on the early detection and prevention of colorectal cancer. The
company has exclusive intellectual property protecting its noninvasive,
molecular screening technology for the detection of colorectal cancer.
Stool DNA technology is included in the colorectal cancer screening
guidelines of the American Cancer Society and the U.S. Multi-Society
Task Force on Colorectal Cancer. For more information, please visit the
company's website at www.exactsciences.com,
follow us on Twitter @ExactSciences
or find us on Facebook.
Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities and Exchange Act of
1934, as amended that are intended to be covered by the “safe harbor”
created by those sections.Forward-looking statements, which are
based on certain assumptions and describe our future plans, strategies
and expectations, can generally be identified by the use of
forward-looking terms such as “believe,” “expect,” “may,” “will,”
“should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or
other comparable terms.Forward-looking statements in this news
release may address the following subjects among others: statements
regarding the sufficiency of our capital resources, our ability to
secure favorable reimbursement rates from Medicare and other third-party
payors, timing of our launch of a commercial product, our estimates of
the available market size and our potential penetration, expected
research and development expenses, expected general and administrative
expenses and our expectations concerning our business strategy.Forward-looking
statements involve inherent risks and uncertainties which could cause
actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management’s
Discussion and Analysis of Financial Condition and Results of Operations
sections of our most recently filed Annual Report on Form 10-K and
our subsequently filed Quarterly Reports on Form 10-Q.We
urge you to consider those risks and uncertainties in evaluating our
forward-looking statements.We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only as
of the date made.Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to publicly
release any updates or revisions to any forward-looking statement
contained herein (or elsewhere) to reflect any change in our
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
Contacts:
Media Contacts:
Exact Sciences
Cara Tucker, 614-302-5622
ctucker@exactsciences.com
or
MSLGROUP
781-684-0770
exactsciences@mslgroup.com
Source: Exact Sciences Corp.
© 2024 Canjex Publishing Ltd. All rights reserved.